Madrigal Pharmaceuticals
NEWS
Intercept’s failure to secure FDA approval for obeticholic acid (OCA) tablets in non-alcoholic steatohepatitis shines a light on safety challenges in the space, experts told BioSpace.
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
Madrigal’s NASH drug hits the mark in late-stage trial.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
Shares of Madrigal Pharmaceuticals went up in premarket trading after the company announced positive topline data from its Phase III assessment of resmetirom in non-alcoholic fatty liver disease.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Not surprisingly, the week between Christmas and New Year was quiet in terms of clinical trial news. However, there were some announcements. Here’s a look.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
JOBS
IN THE PRESS